Results of regional portal infusion of 5-fluorouracil in patients with primary and secondary liver cancer.
The survival of 47 patients with liver malignancies treated with continuous portal infusion of fluorouracil (5-FU) has been studied. 18 of them had been treated initially by hepatic artery ligation. Total mean survival was 9.4 months. Patients treated with hepatic artery ligation + 5-FU lived longer (mean 10.8 months) than those treated with 5-FU alone (7.4 months). The survival was longer than could be expected for patients treated for primary liver cancer or for liver metastases from colo-rectal cancer, when compared with the "untreated" group. It is concluded that continuous portal infusion of 5-FU appears to prolong survival in some groups of patients with malignant liver tumours. However, the influence of "unspecific, general" therapy is difficult to evaluate.
D000328:Adult; D000368:Aged; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage* / Q000097:blood / Q000627:therapeutic use; D006499:Hepatic Artery / Q000601:surgery; D006801:Humans; D007263:Infusions, Parenteral; D008026:Ligation; D008113:Liver Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000601:surgery; D008297:Male; D008875:Middle Aged; D009362:Neoplasm Metastasis; D011169:Portal Vein
D005472:Fluorouracil